Xeltis Steps Up Conference Engagement as aXess Advances Toward Commercialization

According to a recent LinkedIn post from Xeltis, the company expects an intensive conference schedule in 2026 focused on its regenerative vascular access conduits, particularly its lead candidate aXess, as it progresses toward commercialization. The post outlines participation in several scientific and partnering events across Europe and Latin America, where senior leadership and clinical specialists are slated to present and engage with stakeholders.

The company’s LinkedIn post highlights appearances at BIO Capital Europe in Amsterdam, Gemav in Madrid, the European Vascular Course in Maastricht, IMEndo in Rome, Innovation for Health in Utrecht, LSX World Congress in Lisbon, and the SAVE Vascular Access and Endovascular Nephrology Meeting in São Paulo. Xeltis executives, including the CEO and CMO, are expected to deliver presentations and join panels, suggesting a coordinated effort to raise visibility and build partnerships.

For investors, the post suggests Xeltis is prioritizing both clinical engagement and business development as it moves aXess toward market entry. Frequent presence at high-profile vascular and medtech forums could support data dissemination, key opinion leader adoption, and potential partnering or funding discussions, which may be important precursors to future revenue generation.

Participation in events such as LSX World Congress, where market access and U.S. positioning are on the agenda, may indicate that Xeltis is exploring global commercialization pathways beyond its European base. While the post does not disclose new clinical or regulatory milestones, the scope and geographic spread of activities may signal an acceleration of go-to-market planning and a focus on establishing competitive positioning in vascular access solutions.